Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Beigene Ltd (BGNE)  
$160.77 1.40 (0.86%) as of 4:30 Tue 5/14


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 90,630,000
Market Cap: 14.57(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $129.52 - $244.6
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  664
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 100,397 100,397 5,364,251 5,588,274
Total Sell Value $15,909,372 $15,909,372 $1,039,781,980 $1,085,894,829
Total People Sold 2 2 8 9
Total Sell Transactions 6 6 20 54
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 527
  Page 18 of 22  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Liang Howard CFO & Chief Strategy Officer   •       –      –    2018-03-19 4 AS $158.45 $4,702,985 D/D (29,128) 0     -
   Liang Howard CFO & Chief Strategy Officer   •       –      –    2018-03-19 4 OE $6.50 $156,832 D/D 24,128 29,128     -
   Liang Howard CFO & Chief Strategy Officer   •       –      –    2018-03-16 4 AS $154.95 $1,707,666 D/D (10,872) 5,000     -
   Liang Howard CFO & Chief Strategy Officer   •       –      –    2018-03-16 4 OE $6.50 $70,668 D/D 10,872 15,872     -
   Glazer Donald W. Director   –       •      –    2018-03-13 4 GD $0.00 $0 D/D 199,992 4,327,642     -
   Oyler John Chief Executive Officer   •       •       •   2018-03-02 4 AS $141.62 $3,756,784 D/D (25,362) 0     -
   Oyler John Chief Executive Officer   •       •       •   2018-03-01 4 AS $139.08 $5,623,205 D/D (39,300) 25,362     -
   Li Ji EVP and Gl. Head of Bus. Dev.   •       –      –    2018-02-28 4 AS $143.72 $1,468,760 D/D (10,000) 0     -
   Li Ji EVP and Gl. Head of Bus. Dev.   •       –      –    2018-02-28 4 OE $26.65 $266,500 D/D 10,000 10,000     -
   Oyler John Chief Executive Officer   •       •       •   2018-02-28 4 AS $143.48 $5,036,943 D/D (34,338) 64,662     -
   Glazer Donald W. Director   –       •      –    2018-01-26 4 GD $0.00 $0 D/D 10,873 4,527,634     -
   Baker Julian Director   –       •       •   2018-01-18 4 B $101.00 $199,999,998 I/I 1,980,198 5,121,404 2.25     -
   Oyler John Chief Executive Officer   •       •       •   2017-12-26 4 AS $95.55 $1,942,515 D/D (20,137) 99,000     -
   Huang Jane CMO, Hematology   •       –      –    2017-12-21 4 S $98.00 $98,000 D/D (1,000) 0     -
   Huang Jane CMO, Hematology   •       –      –    2017-12-21 4 OE $29.51 $29,510 D/D 1,000 1,000     -
   Huang Jane CMO, Hematology   •       –      –    2017-12-13 4 S $94.21 $141,381 D/D (1,500) 0     -
   Huang Jane CMO, Hematology   •       –      –    2017-12-13 4 OE $29.51 $44,265 D/D 1,500 1,500     -
   Oyler John Chief Executive Officer   •       •       •   2017-12-08 4 AS $94.91 $5,047,758 D/D (52,817) 119,137     -
   Oyler John Chief Executive Officer   •       •       •   2017-12-07 4 AS $92.06 $5,579,304 D/D (59,737) 171,954     -
   Oyler John Chief Executive Officer   •       •       •   2017-12-06 4 AS $91.48 $2,902,224 D/D (31,446) 231,691     -
   Huang Jane CMO, Hematology   •       –      –    2017-12-04 4 AS $86.00 $94,600 I/I (1,100) 0     -
   Oyler John Chief Executive Officer   •       •       •   2017-11-29 4 AS $82.92 $3,013,458 D/D (36,340) 263,137     -
   Oyler John Chief Executive Officer   •       •       •   2017-11-28 4 AS $85.52 $2,820,864 D/D (32,985) 299,477     -
   Oyler John Chief Executive Officer   •       •       •   2017-11-27 4 AS $86.75 $1,438,582 D/D (16,581) 332,462     -
   Huang Jane CMO, Hematology   •       –      –    2017-11-20 4 AS $87.00 $87,000 I/I (1,000) 1,100     -
  527 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 18 of 22
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us